Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial

作者：Franco Maggiolo, Giuliano Rizzardini, François Raffi, Federico Pulido, Maria Gracia Mateo-Garcia, Jean‐Michel Molina, Edmund Ong, Yongwu Shao, David Piontkowsky, Moupali Das, Ian R. McNicholl, Richard Haubrich · 发表于：The Lancet HIV · 年份：2019 · DOI：10.1016/s2352-3018(19)30195-x · 被引用次数：43 · 研究领域：HIV-related health complications and treatments、HIV/AIDS drug development and treatment、HIV Research and Treatment